Research Analysts Offer Predictions for TRDA Q3 Earnings

Key Points

• Roth Capital has revised its Q3 2025 earnings estimate for Entrada Therapeutics, anticipating a loss of ($1.13) per share, down from a prior estimate of ($0.97).
• Wall Street Zen downgraded Entrada Therapeutics from a "hold" rating to a "sell" rating, while HC Wainwright maintained a "buy" rating with a price target of $20.00.
• In its latest quarterly earnings, Entrada reported a loss of ($1.04) per share, which missed the consensus estimate by ($0.18), alongside revenues of just $1.98 million compared to expected $8.17 million.

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Equities researchers at Roth Capital reduced their Q3 2025 earnings per share estimates for Entrada Therapeutics in a note issued to investors on Wednesday, August 6th. Roth Capital analyst B. Pachaiyappan now anticipates that the company will earn ($1.13) per share for the quarter, down from their previous forecast of ($0.97). The consensus estimate for Entrada Therapeutics' current full-year earnings is $1.12 per share. Roth Capital also issued estimates for Entrada Therapeutics' Q4 2025 earnings at ($1.26) EPS, FY2025 earnings at ($3.86) EPS, Q1 2026 earnings at ($1.32) EPS, Q2 2026 earnings at ($1.38) EPS, Q3 2026 earnings at ($1.45) EPS, Q4 2026 earnings at ($1.51) EPS and FY2026 earnings at ($5.66) EPS.

Other equities research analysts have also issued research reports about the company. HC Wainwright restated a "buy" rating and set a $20.00 price objective on shares of Entrada Therapeutics in a research note on Tuesday, May 20th. Wall Street Zen lowered Entrada Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, August 9th. One analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $25.67.

Entrada Therapeutics Stock Performance

Shares of TRDA stock traded down $0.18 during trading hours on Monday, reaching $5.14. The company had a trading volume of 42,810 shares, compared to its average volume of 148,093. Entrada Therapeutics has a twelve month low of $4.93 and a twelve month high of $21.79. The stock's fifty day simple moving average is $6.72 and its 200 day simple moving average is $8.86. The company has a market capitalization of $195.51 million, a P/E ratio of -2.89 and a beta of -0.12.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($1.04) EPS for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.18). Entrada Therapeutics had a negative return on equity of 17.81% and a negative net margin of 92.30%. The firm had revenue of $1.98 million during the quarter, compared to analysts' expectations of $8.17 million.

Insider Activity at Entrada Therapeutics

In other news, Director Kush Parmar sold 27,000 shares of the firm's stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $7.50, for a total value of $202,500.00. Following the completion of the transaction, the director owned 1,093,313 shares in the company, valued at $8,199,847.50. This trade represents a 2.41% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Ventures V. L.P. 5Am sold 6,935 shares of Entrada Therapeutics stock in a transaction that occurred on Wednesday, July 9th. The shares were sold at an average price of $7.50, for a total transaction of $52,012.50. Following the completion of the sale, the insider owned 1,093,313 shares of the company's stock, valued at approximately $8,199,847.50. The trade was a 0.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 254,000 shares of company stock worth $1,782,000. Corporate insiders own 8.11% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Merck & Co. Inc. bought a new stake in shares of Entrada Therapeutics in the first quarter worth $15,728,000. Janus Henderson Group PLC boosted its position in shares of Entrada Therapeutics by 21.6% during the 4th quarter. Janus Henderson Group PLC now owns 2,080,367 shares of the company's stock worth $36,011,000 after purchasing an additional 368,908 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Entrada Therapeutics by 19.7% in the 4th quarter. Vanguard Group Inc. now owns 1,464,237 shares of the company's stock worth $25,317,000 after acquiring an additional 241,052 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Entrada Therapeutics by 127.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 217,006 shares of the company's stock valued at $3,752,000 after buying an additional 121,598 shares during the last quarter. Finally, Qube Research & Technologies Ltd increased its stake in Entrada Therapeutics by 435.1% in the 2nd quarter. Qube Research & Technologies Ltd now owns 133,730 shares of the company's stock valued at $899,000 after buying an additional 108,737 shares during the last quarter. 86.39% of the stock is currently owned by institutional investors and hedge funds.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.